###begin article-title 0
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
Absence of AKT1 Mutations in Glioblastoma
###end article-title 0
###begin p 1
Conceived and designed the experiments: FB AAGvT AB. Performed the experiments: FB SL CZ. Analyzed the data: FB SL. Contributed reagents/materials/analysis tools: FB AAGvT SL DT TH WPV AB. Wrote the paper: FB WPV AB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
###xml 415 419 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Oncogenic activation of the PI3K signalling pathway plays a pivotal role in the development of glioblastoma multiforme (GBM). A central node in PI3K downstream signalling is controlled by the serine-threonine kinase AKT1. A somatic mutation affecting residue E17 of the AKT1 gene has recently been identified in breast and colon cancer. The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. Assessing whether AKT1 is activated by somatic mutations in GBM is relevant to establish its role in this aggressive disease.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
We performed a systematic mutational analysis of the complete coding sequence of the AKT1 gene in a panel of 109 tumor GBM samples and nine high grade astrocytoma cell lines. However, no somatic mutations were detected in the coding region of AKT1.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
Our data indicate that in GBM oncogenic deregulation of the PI3K pathway does not involve somatic mutations in the coding region of AKT1.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 127 130 127 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Brugge1">[1]</xref>
###xml 132 135 132 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Wood1">[2]</xref>
###xml 335 338 335 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Knobbe1">[3]</xref>
###xml 340 343 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Kita1">[4]</xref>
###xml 488 494 488 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 547 550 547 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Kita1">[4]</xref>
###xml 551 554 551 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Benvenuti1">[7]</xref>
###xml 817 821 817 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 918 921 918 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Li1">[8]</xref>
###xml 963 969 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 974 978 974 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1026 1029 1026 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Hartmann1">[6]</xref>
###xml 1031 1034 1031 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Saal1">[9]</xref>
###xml 1187 1191 1187 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Stephens1">[10]</xref>
###xml 1193 1197 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Maehama1">[11]</xref>
###xml 1392 1396 1392 1396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1459 1463 1459 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Lee1">[12]</xref>
###xml 1537 1545 1537 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFRvIII</italic>
###xml 1612 1616 1612 1616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1763 1767 1763 1767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Lee1">[12]</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
A number of genetic and functional evidences have unequivocally established the importance of the PI3K pathway in human cancer [1], [2]. For example oncogenic deregulation of the PI3K pathway plays a central role in the development of Glioblastoma Multiforme (GBM) as shown by the fact that many of its members are genetically altered [3], [4]. Two main regulators, the lipid kinase PIK3CA and the lipid phosphatase PTEN, control this signalling pathway. We and other have shown that the PIK3CA gene is mutated in many tumour types, including GBM [4]-[7]. The corresponding mutations result in activation of the PI3K catalytic activity and constitutive downstream signalling. The tumour suppressor gene PTEN encodes for a lipid phopshatase which counteracts the effect of PI3K thus negatively controlling signalling. PTEN is mutationally and transcriptionally inactivated in many different tumour types, including GBM [8]. In most tumour lineages, including GBMs PIK3CA and PTEN mutations occur in a mutually exclusive manner [6], [9]. This suggests that they exert overlapping cellular functions, and in fact, both control the cellular levels of phosphatidylinositol-3-phosphate (PIP3) [10], [11]. Other mechanisms of activation of the PI3K pathway include alterations in tyrosine kinase receptors acting upstream in the signalling cascade. This is the case for the receptor tyrosine kinase EGFR which can be activated by gene amplification and/or mutations [12]. Both missense point mutations and large extracellular domain deletions (EGFRvIII, which due to alternative splicing misses exon 2-7) affecting the EGFR gene have been reported at considerable frequency in GBM and result in constitutive activation of the receptor and of the underlying PI3K pathway [12].
###end p 9
###begin p 10
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Carpten1">[13]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Carpten1">[13]</xref>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Malanga1">[14]</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Schuller1">[17]</xref>
###xml 836 840 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Malanga1">[14]</xref>
###xml 842 846 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Bleeker1">[15]</xref>
###xml 954 958 954 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Bleeker1">[15]</xref>
###xml 1085 1089 1085 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1094 1099 1094 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 1156 1160 1156 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Lynch1">[18]</xref>
###xml 1162 1166 1162 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Stephens2">[19]</xref>
###xml 1249 1253 1249 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Lee1">[12]</xref>
###xml 1255 1259 1255 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Parsons1">[20]</xref>
###xml 1341 1345 1341 1345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
###xml 1450 1454 1450 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
###xml 609 613 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Downstream in the signaling cascade, PI3K and PTEN control PIP3, which activates downstream effector molecules, such as the serine-threonine kinase AKT. A recent sequencing study led to the identification of oncogenic somatic mutations in the pleckstrin homology domain of AKT1 in breast, colon and ovarian cancer [13]. Interestingly, in all cases examined the same mutation E17K was identified. This mutation alters the electrostatic interactions of the pocket and constitutively activates AKT1 in a PI3K-independent manner. By this mechanism, it transforms rodent cells in vitro and can induce leukaemia in mice [13]. Recently, we and others assessed the mutational status of the E17K mutation in different tumor types [14]-[17], confirming the mutations in breast and colon, and most interestingly revealing mutations in lung cancer [14], [15]. On the contrary, we did not detect any mutations affecting the hotspot residue E17 in a panel of 128 GBMs [15]. We noted that, GBMs do exhibit a different mutation spectrum for some genes compared to other tumor types. For example, most EGFR and ERBB2 mutations in lung cancer are found in the kinase domain [18], [19], whereas these genes are predominantly mutated in the extracellular domain in GBM [12], [20]. This led us to speculate that GBMs might bear mutations in other regions of the AKT1 gene. To definitively assess this hypothesis, we successfully sequenced the complete coding sequence of AKT1 in 109 GBM tumor samples and nine high grade astrocytoma cell lines.
###end p 10
###begin title 11
Results and Discussion
###end title 11
###begin p 12
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
###xml 229 233 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
We sequenced the complete coding sequence of the AKT1 gene in a set of 109 GBM tumors and 9 high grade astrocytoma cell lines. Primers were designed to amplify and sequence the genomic region corresponding to all coding exons of AKT1, including exon 4, where the E17K residue is located. Amplicons included at least 15 intronic bases at both the 5' and 3' ends encompassing the splicing donor and acceptor sites. A total of 1535 PCR products, spanning 628 kb of tumour genomic DNA, were generated and subjected to direct sequencing. Sequencing was performed single stranded with either forward or reverser primer. Identified changes were independently confirmed by another round of PCR and sequencing.
###end p 12
###begin p 13
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Bleeker1">[15]</xref>
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
Previous work focusing on the mutational analysis of exon 4 did not identify any E17K mutation in 128 GBM samples [15]. Importantly, we extended the mutational analysis for these tumors to all other coding exons of AKT1, but no somatic mutations were found.
###end p 13
###begin p 14
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IDH1</italic>
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Bleeker2">[21]</xref>
Our tumor set was validated by previous mutational profiling of common cancer genes, including the IDH1 gene [21]. Furthermore, we found a number of previous reported SNPs in our samples (rs17846822, rs34664585, rs3730358, rs3730368, rs2494737, rs2494735, rs34670300, rs3730361, rs3730329, rs3730329, rs2494732). In addition, we identified three novel germline changes (IVS8-12C>T, R200H and W333*) at low frequency, they were found only once in different samples. Our work is focused on somatic mutations and therefore, we did not study these changes in further detail.
###end p 14
###begin p 15
###xml 76 79 76 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E17</sup>
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1<sup>E17</sup></italic>
###xml 129 132 129 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Knobbe1">[3]</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Bleeker1">[15]</xref>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Schuller1">[17]</xref>
###xml 347 351 347 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
###xml 499 503 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT1</italic>
While previous studies have focused mainly on the hotspot mutation site AKT1E17or the serine and threonine phosphorylation sites [3], [15], [17], this work is the first to show in a large panel of GBMs that the coding sequence of the AKT1 is not somatically mutated in this tumour lineage. Although the promoter region and/or the 5' and 3' UTR of AKT1 may contain mutations, our data indicate that in GBM oncogenic deregulation of the PI3K pathway does not involve mutations in the coding region of AKT1.
###end p 15
###begin title 16
Materials and Methods
###end title 16
###begin title 17
Tumor sample, Ethics Statement and Isolation of Genomic DNA
###end title 17
###begin p 18
###xml 494 501 494 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005638-t001">Table 1</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 263 270 <span type="species:ncbi:9606">patient</span>
###xml 453 460 <span type="species:ncbi:9606">Patient</span>
All samples were collected from patients undergoing brain tumor surgery in the Academic Medical Center (Amsterdam, The Netherlands). Oral consent for removal of the tissue and its storage in the tumor bank for research purposes was obtained and documented in the patient's medical chart. Individual consent for this specific project was waivered by our ethics committee because the research was performed on 'waste' material, stored in a coded fashion. Patient characteristics are displayed in Table 1. Tumor samples were included only if at least 80% of the sample consisted of cancer cells, as verified by H&E staining.
###end p 18
###begin title 19
Characteristics of 109 GBM tumor samples.
###end title 19
###begin p 20
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005638-Balakrishnan1">[22]</xref>
Nine astrocytoma cell lines were included: the cell lines U87MG, U118MG, U251MG, U373MG, T98G (ATCC, Middlesex, United Kingdom), SKMG-3 (a gift of Dr Christopher Y. Thomas, University of Virginia Division of Hematology/Oncology, Charlottesville, VA), SF763 (gift of Dr M.L. Lamfers, Department of Neurosurgery, Free University, Amsterdam, The Netherlands), SF126 (a gift of Dr C. Van Bree, University of Amsterdam, Laboratory for Experimental Oncology and Radiation Biology, Amsterdam, The Netherlands), Gli-6 was derived from our own laboratory. Genomic DNA was isolated as previously described [22].
###end p 20
###begin title 21
PCR, Sequencing and Analysis
###end title 21
###begin p 22
###xml 119 126 119 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005638-t002">Table 2</xref>
PCR primers were designed using Primer 3 (), and synthesized by Invitrogen/Life Technologies, Inc. (Paisley, England) (Table 2). PCR primers that amplify the selected exons and the flanking intronic sequences, including splicing donor and acceptor regions, were used and PCR products were on average 381 bps in length. PCRs were performed in both 384- and 96-well formats in 5- or 10-uL reaction volumes, respectively, containing 0.25 mmol/L deoxynucleotide triphosphates, 1 umol/L each of the forward and reverse primers, 6% DMSO, 1x PCR buffer, 1 ng/uL DNA, and 0.05 unit/uL Platinum Taq (Invitrogen/Life Technologies). A touchdown PCR program was used for PCR amplification (Peltier Thermocycler, PTC-200, MJ Research, Bio-Rad Laboratories, Inc., Italy).
###end p 22
###begin title 23
Primer details to sequence the coding sequence of AKT1.
###end title 23
###begin p 24
Primers in 5' to 3' direction.
###end p 24
###begin p 25
PCR conditions were as follows: 94degreesC for 2 min; three cycles of 94degreesC for 15 s, 64degreesC for 30 s, 70degreesC for 30 s; three cycles of 94degreesC for 15 s, 61degreesC for 30 s, 70degreesC for 30 s; three cycles of 94degreesC for 15 s, 58degreesC for 30 s, 70degreesC for 30 s; and 35 cycles of 94degreesC for 15 s, 57degreesC for 30 s, and 70degreesC for 30 s, followed by 70degreesC for 5 min and 12degreesC thereafter. PCR products were purified using AMPure (Agencourt Bioscience Corp., Beckman Coulter S.p.A, Milan, Italy). Cycle sequencing was carried out using BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA) with an initial denaturation at 97degreesC for 3 min, followed by 28 cycles of 97degreesC for 10 s, 50degreesC for 20 s, and 60degreesC for 2 min. Sequencing products were purified using CleanSeq (Agencourt Bioscience, Beckman Coulter) and analyzed on a 3730 DNA Analyzer, ABI capillary electrophoresis system (Applied Biosystems). Sequence traces were analyzed using the Mutation Surveyor software package (SoftGenetics, State College, PA).
###end p 25
###begin title 26
References
###end title 26
###begin article-title 27
A new mutational AKTivation in the PI3K pathway.
###end article-title 27
###begin article-title 28
###xml 26 31 <span type="species:ncbi:9606">human</span>
The genomic landscapes of human breast and colorectal cancers.
###end article-title 28
###begin article-title 29
###xml 103 108 <span type="species:ncbi:9606">human</span>
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.
###end article-title 29
###begin article-title 30
PIK3CA alterations in primary (de novo) and secondary glioblastomas.
###end article-title 30
###begin article-title 31
###xml 50 55 <span type="species:ncbi:9606">human</span>
High frequency of mutations of the PIK3CA gene in human cancers.
###end article-title 31
###begin article-title 32
PIK3CA mutations in glioblastoma multiforme.
###end article-title 32
###begin article-title 33
PIK3CA cancer mutations display gender and tissue specificity patterns.
###end article-title 33
###begin article-title 34
###xml 62 67 <span type="species:ncbi:9606">human</span>
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
###end article-title 34
###begin article-title 35
###xml 124 129 <span type="species:ncbi:9606">human</span>
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
###end article-title 35
###begin article-title 36
Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils.
###end article-title 36
###begin article-title 37
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
###end article-title 37
###begin article-title 38
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
###end article-title 38
###begin article-title 39
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
###end article-title 39
###begin article-title 40
Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung.
###end article-title 40
###begin article-title 41
###xml 14 19 <span type="species:ncbi:9606">human</span>
AKT1(E17K) in human solid tumours.
###end article-title 41
###begin article-title 42
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
###end article-title 42
###begin article-title 43
Absence of mutations in the AKT1 oncogene in glioblastomas and medulloblastomas.
###end article-title 43
###begin article-title 44
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
###end article-title 44
###begin article-title 45
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
###end article-title 45
###begin article-title 46
###xml 34 39 <span type="species:ncbi:9606">Human</span>
An Integrated Genomic Analysis of Human Glioblastoma Multiforme.
###end article-title 46
###begin article-title 47
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
###end article-title 47
###begin article-title 48
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.
###end article-title 48
###begin p 49
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 49
###begin p 50
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from Italian Association for Cancer Research (AIRC: (AB), Italian Ministry of Health, Regione Piemonte (AB), Italian Ministry of University and Research, CRT Progetto Alfieri (AB), Association for International Cancer Research (AICR-UK: AB), EU FP6 contract 037297 (AB) and Netherlands Genomic Initiative (NGI: FB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 50

